A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2021-07-07
Target enrollment:
Participant gender:
Summary
This multicenter, randomized, double-blind, placebo controlled, parallel group study is being
conducted to provide data on efficacy, safety, tolerability and pharmacokinetics (PK) of
multiple dose levels of PF-06882961 in adults with type 2 diabetes mellitus (T2DM)
inadequately controlled on metformin and/or diet and exercise. In addition, the study is
intended to enable selection of efficacious doses for future clinical development of
PF-06882961.